<DOC>
	<DOCNO>NCT00374192</DOCNO>
	<brief_summary>To examine change sleep pattern mood symptom response eszopiclone ( Lunesta ) use double-blind placebo-controlled cross-over study design perimenopausal postmenopausal woman experience insomnia , mild depression and/or anxiety .</brief_summary>
	<brief_title>The Treatment Insomnia Symptomatic Peri- Postmenopausal Women</brief_title>
	<detailed_description>The study design double-blinded placebo-controlled cross-over study complete MGH site . It 11-week study insomnia , mild mood , anxiety symptom peri- postmenopausal woman age 40 year old . Subjects enrol 5 office visit 11-week long study . Various study identify female gender strong risk factor insomnia , ( Ford &amp; Kamerow , 1989 ; Klink et al , 1992 ; Li et al , 2002 ) ; community-based study examine gender difference insomnia complaint consistently show high prevalence insomnia among woman among men . It hypothesize insomnia might overlook complaint among woman seek treatment primary care set . Insomnia sleep disturbance may report specific situation associate female reproductive cycle , pregnancy ( Sahota et al , 2003 ) menopause ( Joffe et al , 2003 ) . Complaints sleep-onset sleep-maintenance insomnia among common symptom peri- postmenopausal woman . This sleep disturbance frequently co-occurs hot flush depression symptom . The menopausal transition also period heighten vulnerability mood anxiety disturbance , significant vasomotor symptom ( i.e . hot flush night sweat ) may affect function quality life . Consented subject track sleep pattern one week use sleep diary confirm either difficulty initiate sleep ( ³ 30 minute ) difficulty maintain sleep ( wake time sleep onset ³ 30 ) , ≥ 3 night 7-day observation period . Those confirmed meet insomnia criterion randomize 1-to-1 fashion cross-over treatment start either eszopiclone placebo . In addition take daily medication , come office visit , subject complete daily diary throughout study . This diary complete assess insomnia symptom throughout duration study . Treatment assignment reveal final study visit participant , research coordinator , study physician .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>1 . Women 40+ year old . 2 . Subject must follow perimenopausal postmenopausal sign symptom define Stages Reproductive Aging Workshop ( STRAW ) : 1 . Early Menopausal Transition ( Stage 2 ) : Variable cycle length &gt; 7 day different normal . 2 . Late Menopausal Transition ( Stage 1 ) : &gt; 2 skip cycle interval amenorrhea &gt; 60 day . 3 . Post Menopause ( Stage +1 ) : Amenorrhea least 12 month . 4 . Surgical Post Menopause 5 . Hysterectomized woman one ovary preserve eligible FSH level &gt; 20 IU/L . 6 . If hormonal therapy , history menstrualcycle abnormality consistent 2a2e indicate peri/postmenopausal status prior initiation hormonal therapy . 3 . One follow insomnia symptom ³ 3 night per week least one month prior study enrollment : 1 . Difficulty initiate sleep ( ³ 30 minute ) 2 . Difficulty maintain sleep ( wake time sleep onset ³ 30 minute ) 4 . Daytime function wellbeing impaired result insomnia . 5 . Mild depression and/or anxiety screen visit define : 1 . Mild Depressive symptom define MontgomeryÅsberg Depression Rating ScaleMADRS ( MADRS ) ³ 10 administer screen visit , 2 . Mild Anxiety symptom define Beck Anxiety Inventory ( BAI ) ³ 10 administer screen visit . 6 . May ( require ) hot flush 7 . May ( require ) develop insomnia discontinuation hormonal therapy . 8 . If subject antidepressant , must stable dos least 2 month . 9 . If subject hormonal therapy , dose must stable least 2 month . 10 . General Good Health 1 . According M.I.N.I ( Mini International Neuropsychiatric Interview ) , subject meet current past criterion past 3 month : 1 . Major Depression 2 . Dysthymia 3 . Panic disorder 4 . PTSD ( PostTraumatic Stress Disorder ) 2 . According M.I.N.I , subject evidence current suicidal ideation , homicidal ideation , psychotic symptom screen visit . 3 . Suicide attempt past 5 year . 4 . According M.I.N.I , subject meet criteria substance use disorder diagnosis within past 5 year . 5 . Subject current recent use ( past month use &gt; 25 % time ) hypnotic agent . 6 . Subject antidepressant hormone therapy past 2 month . ( Unless take currently stable dose ≥ 2 month ) . 7 . Subject : 1 . Unstable medical abnormality 2 . Unstable chronic disease . 8 . History significant cardiac , renal , hepatic disease , seizure disorder . 9 . Regular use disallow medication ( Including ; Clarithromycin , Itraconazole , Ketoconazole , Nefazodone , Nelfinavir , Olanzapine , Rifampin , Ritonavir , Troleandomycin ) currently past month . 10 . Subject disorder history condition ( e.g. , malabsorption , gastrointestinal surgery ) may interfere drug absorption , distribution , metabolism , excretion . 11 . Subject previously diagnose sleep apnea , restless leg syndrome ( RLS ) , periodic leg movement syndrome ( PLMS ) , condition may affect sleep ( e.g. , chronic pain , urinary incontinence , etc. ) . 12 . Subject report consumption two alcoholic beverage daily , 14 alcoholic beverage weekly , five alcoholic beverage give day past month . 13 . Currently pregnant breastfeed 14 . Subject rotate third/night shift worker . 15 . Subject often travel across multiple time zone . 16 . Subject currently enrol another clinical trial , subject participate investigational drug study within 30 day prior screen , plan participate another investigational drug study participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Sleep</keyword>
	<keyword>Lunesta</keyword>
	<keyword>Quality Life</keyword>
</DOC>